Literature DB >> 10494758

Venous thrombosis, oral contraceptives and high factor VIII levels.

K W Bloemenkamp1, F M Helmerhorst, F R Rosendaal, J P Vandenbroucke.   

Abstract

Recently, it has been described that elevated plasma levels of factor VIII are a strong risk factor for venous thrombosis. We analysed the data of the Leiden Thrombophilia Study, a population based case-control study on the causes of venous thrombosis, to verify whether the risk due to oral contraceptive use was higher in women with higher factor VIII levels. Furthermore we investigated the joint risk of high factor VIII levels and oral contraceptive use. We selected 155 premenopausal women with deep-vein thrombosis and 169 control subjects, aged 15-49, who were at the time of their thrombosis (or similar date in control) not pregnant, nor in the puerperium, did not have a recent miscarriage, and were not using injectable progestogens. Of the patients, 109 (70%) women had used oral contraceptives during the month preceding their deep-vein thrombosis, in contrast to 65 (38%) of the control subjects (index date), yielding an odds ratio for oral contraceptive use of 3.8 (95% CI 2.4-6.0). Of the women who suffered a deep-vein thrombosis 56 (36%) had high factor VIII levels (> or =150 IU/dl) as compared with 29 (17%) of the control subjects, yielding an odds ratio for high factor VIII of 4.0 (95% CI 2.0-8.0), relative to factor VIII levels <100 IU/dl. The joint effect of oral contraceptive use and high factor VIII resulted in an odds ratio of 10.3 (95% CI 3.7-28.9), comparing women who had both with women who had neither. We conclude that there is an increase in risk due to oral contraceptive use in women with higher factor VIII levels and that both factors have additive effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494758

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Elevated factor VIII and portal vein thrombosis.

Authors:  Venodhar R Julapalli; Paul F Bray; Andrea Duchini
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

2.  Endogenous thrombin potential changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Malcolm C Pike; Serge Cremers; Andrew Eisenberger; Stella Thomassen; Jan Rosing
Journal:  Contraception       Date:  2017-01-11       Impact factor: 3.375

3.  Cerebral venous thrombosis associated with thyrotoxicosis, the use of desmopressin and elevated factor VIII/von Willebrand factor.

Authors:  Waqar Waheed; Salman Aljerdi; Barbara Decker; Mary Cushman; Robert W Hamill
Journal:  BMJ Case Rep       Date:  2016-08-08

4.  Flow-simulated thrombin generation profiles as a predictor of thrombotic risk among pre-menopausal women.

Authors:  Sumanas W Jordan; Matthew A Corriere; Carla Y Vossen; Frits R Rosendaal; Elliot L Chaikof
Journal:  Thromb Haemost       Date:  2012-06-12       Impact factor: 5.249

Review 5.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

6.  Clotting factor changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Andrew Eisenberger; Rosalind Tang; Serge Cremers; Lisa V Grossman; Malcolm C Pike
Journal:  Contraception       Date:  2015-10-09       Impact factor: 3.375

7.  Recurrent myocardial infarctions in a young football player secondary to thrombophilia, associated with elevated factor VIII activity.

Authors:  Thomas P Vacek; Shipeng Yu; Shahnaz Rehman; Blair P Grubb; Daniel Kosinski; Cherian Verghese; Ehab A Eltahawy; Qaiser Shafiq
Journal:  Int Med Case Rep J       Date:  2014-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.